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A set of benzofuroxan derivatives was tested in vitro against Trypanosoma cruzi epimastigote forms.
The influence of physicochemical properties on these benzofuroxan derivatives’ activity was observed,
and the presence of electron-withdrawing and hydrophobic groups attached to the benzene ring seems
to make a favorable contribution at lower concentrations.
The search for new therapeutic options is a continuous need
when the so-called neglected diseases are considered. One of the
main reasons for this designation is the lack of interest from
major pharmaceutical companies in investing money into the
research and development (R&D) for new drugs concerning
these diseases, since the investments would hardly be returned as
profits.1,2 Neglected diseases primarily affect underdeveloped
countries in Africa, Asia, and Latin America, especially in areas
where sanitation and housing are precarious, with little or no
access to health care.1,3 According to the World Health Organi-
zation (WHO), it is estimated that 1 billion people, almost one
sixth of the global population, suffer from one or more neglected
diseases.4
Chagas disease (CD) is considered one of the thirteen ‘‘most’’
neglected diseases,1,5 being part of a group that receives less than
5% investments into R&D programs.6 This parasitic disease,
caused by the protozoal hemoflagellate Trypanosoma cruzi, is
endemic in twenty one Latin American countries and presents
a death rate of approximately 14 000 people per year, which is
higher than any other vector-transmitted disease, including
malaria.6
Since the 1970s, the clinical treatment for CD is dependent on
only two drugs, benznidazole (Rochagan, Roche) and nifurti-
mox (Lampit, Roche). Furthermore, the use of these two drugs
in clinical practice is controversial, since neither promotes
healing in the chronic phase and both show several adverse
effects in infected patients.7 The high toxicity of these two drugs,
which is represented by the side effects, joined with the emer-
gence of T. cruzi resistant strains, reinforces the need for new
therapeutic options with better pharmacological profiles.
Previous studies of benzofuroxan derivatives, structurally
analogous to nifuroxazide (see Fig. 1), demonstrated the influ-
ence of physicochemical properties on the antibacterial activity
against multidrug-resistant Staphylococcus aureus strains.8,9 In
order to continue the research on the potential of these
compounds, in this study the anti-T. cruzi activity of a series of
twenty N0-(benzofuroxan-5-yl)methylenebenzohydrazides was
investigated in vitro. The use of the benzofuroxan system as
a bioreductive pharmacophore and also as a cruzipain inhibitor
has been described as an alternative in the search for new anti-
chagasic drugs.10 The series was designed to explore the influence
of physicochemical properties such as the electronic effect (s)
and hydrophobicity (p), based on the Craig diagram.11
Fig. 1 Chemical structural of nifuroxazide and a set of benzofuroxan
derivatives.
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The s constant, defined by Hammett, characterizes the elec-
tronic behavior of a substituent group. The absolute values of s
reflect the magnitude of the electronic effect, whether inductive
or resonance, conveyed the substituent on the reaction center or
on the physicochemical measure. Positive values of s are
observed for electron withdrawing substituent groups, while
negative values are observed in electron-donating substitu-
ents.12,13 The p constant, defined by Hansch–Fujita, has been
widely used as a measure of the hydrophobic contribution of
substituent groups, and measures the individual contribution of
these groups to the partition coefficient of a molecule. The
position of the substituent group has a major influence on the p
constant’s value and it is possible to verify different values for the
same substituent group according to its position in the molecule.
By definition, positive values of p are found for groups with
lipophilic behavior and negative values for hydrophilic
groups.13,14
Eighteen derivatives have already been synthesized and iden-
tified in previous studies,8,15 and 4-ethyl (7) and 4-ethoxy (12)
substituted compounds were included in this investigation to
complete the series. The synthesis of these two new compounds
followed the synthetic path described in the literature.15 The
structure of these new compounds was confirmed by 1H and 13C
NMR spectra (recorded on a Bruker ADPX Advanced spec-
trometer, 300 MHz employing DMSO-d6 solutions with tetra-
methylsilane as internal standard), elemental analysis (performed
on a Perkin-Elmer 24013 CHN Elemental Analyzer) and melting
point (determined using Micro-Quımica MQAPF-301 appa-
ratus). The identification data for both compounds are shown in
the ‘‘Notes and references’’ section.16
In vitro anti-T. cruzi activity assays were performed against the
epimastigote form of T. cruzi Y strain,‡ isolated by Silva and
Nussenzweig in 1953,17 cultured at 28 C in liver infusion tryp-
tose (LIT) medium, and supplemented with 10% heat-inactivated
fetal calf serum. The Y strain is classified as biodeme type I,
which consists of parasites of a slender shape with interstitial
tissue tropism in the acute phase, and a slender shape with
tropism for muscle tissue in the chronic phase. The parasites
multiply rapidly, with a high parasitemia and parasitemic peak
around 10 days, and mortality of the infected animals between 7
and 12 days.18 Furthermore, the use of T. cruzi epimastigote
forms is relevant in a preliminary evaluation of the anti-
proliferative effect of potential antichagasic agents, since those
forms are present in mammalian cells.19,20 Parasites in the loga-
rithmic growth phase (from an initial culture with 1.0  107
Table 1 Biological activity after 72 hours of compounds 1–20 and BZN exposurea
Compound R1 R2 R3
0 hours 10 mg mL1 20 mg mL1 50 mg mL1
Cells per mLb Cells per mLb PGIc Cells per mLb PGIc Cells per mLb PGIc
1 H H H 10.72 21.41 46 6.97 82 2.10 95
2 CH3 H H 10.75 26.20 34 14.98 62 9.65 76
3 NH2 H H 11.53 36.75 7 30.29 24 23.00 42
4 OH H H 12.62 40.63 0 38.36 3 20.80 47
5 F H H 10.99 21.95 45 8.29 79 8.85 78
6 CN H H 11.26 36.37 8 24.04 39 22.12 44
7 CH2CH3 H H 10.09 21.04 47 9.49 76 5.94 85
8 OCH3 H H 10.97 25.54 36 12.09 69 9.59 76
9 Cl H H 10.97 18.05 54 6.66 83 15.00 62
10 COCH3 H H 11.01 34.25 14 25.97 34 6.72 83
11 N(CH3)2 H H 10.19 38.13 4 36.70 7 35.51 10
12 OCH2CH3 H H 10.52 26.90 32 12.83 68 13.39 66
13 NO2 H H 11.01 34.63 13 10.57 73 10.77 73
14 CF3 H H 11.22 13.92 65 5.53 86 6.99 82
15 Br H H 11.00 22.00 44 9.52 76 16.56 58
16 SO2NH2 H H 10.08 37.80 5 36.17 9 34.83 12
17 I H H 10.21 18.15 54 7.61 81 15.88 60
18 Cl H Cl 10.48 23.15 42 11.12 72 4.45 89
19 Cl Cl H 10.66 19.43 51 7.46 81 9.86 75
20 NO2 CF3 H 9.87 18.10 54 7.06 82 7.10 82
BZN 10.33 22.03 44 13.47 66 9.08 77
Positive control 10.53 39.60 0 39.60 0 39.60 0
a Values corresponding to the average of triplicate (standard deviation less than 10% for all cases). b 106 mL1. c PGI (%) ¼ [(Ac3  Ap3)/Ac3]  100,
where Ac3 ¼ A580 of the culture in the absence of the drug at day 3, and Ap3 ¼ A580 of the culture containing the drug at day 3.
Fig. 2 Number of epimastigote forms per mL after exposure to the
compounds 4-Cl (9), 4-CF3 (14), 3-CF3,4-NO2 (20) and BZN. The values
represent the mean of three experiments  SD (standard deviation).
‡ The authors thank Professor Maria Julia Manso Alves of the
Laboratory of Biochemical Parasitology, Department of Biochemistry,
Institute of Chemistry-USP, for providing the Trypanosoma cruzi Y
strain.
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epimastigotes per mL) were incubated with increasing concen-
trations of the test compounds 1–20 (10.0, 20.0 and 50.0 mg
mL1) in DMSO (0.5 and 1.0% final concentration) for 24, 48, 72
and 96 hours.21 Benznidazole (BZN) was used as control drug in
the same concentrations and conditions as the tested compounds.
No effect on epimastigotes’ growth was observed in the presence
of up to 1% (v/v) DMSO in the cultured media. Parasite viability
and growth response were determined by absorbance readings
every 24 h at 580 nm (A580) in a spectrophotometer. All assays
were carried out in triplicate. The activity was determined by
calculating the percentage of growth inhibition (PGI) in the
treated samples against the control in the absence of any drug.
The PGI was calculated as follows: PGI (%) ¼ [(Acn  Apn)/
Acn]  100, where Acn ¼ A580 of the culture in the absence of the
drug at day n (n ¼ 1, 2, 3 or 4), and Apn ¼ A580 of the culture
containing the drug at day n (n¼ 1, 2, 3 or 4).22,23 The absorbance
readings after 72 hours were considered as biological endpoints,23
and Table 1 presents the results regarding the number of para-
sites per mL of the culture after 72 hours of compounds 1–20 and
BZN exposure.
The complete profile for the control, compounds 1–20, and
BZN solutions, the findings regarding the number of parasites
per mL at every reading time for each compound concentration,
and, also, the PGI of the compounds are properly reported in the
ESI†.
The compounds 4-Cl (9), 4-CF3 (14), and 3-CF3,4-NO2 (20)
showed the best activities at 10 mg mL1 concentration. They
were more active than BZN (see Fig. 2). After 72 hours,
compound 14 inhibited around 65% of the parasite growth.
The compounds 4-NH2 (3), 4-OH (4), 4-CN (6), 4-N(CH3)2
(11) and 4-SO2NH2 (16) did not show good activities, and after
72 hours no activity on the parasite growth was observed for
compound 4.
For 20 mg mL1 concentration, the compounds substituted
with hydrophobic (p > 0) and electron-withdrawing (s > 0)
groups, such as 4-F (5), 4-Cl (9), 4-CF3 (14), 4-Br (15), 4-I (17),
3,4-Cl2 (19) and 3-CF3,4-NO2 (20), eliminated the epimastigote
forms inoculated at day 0 and decreased the parasite density over
more than 107 epimastigotes per mL in cultures (see Fig. 3). The
same profile was observed for compounds 4-H (1) and 4-
CH2CH3 (7).
Compound 14 showed the best activity at 20 mg mL1
concentration, which represents a reduction of 86% over the
normal parasitary growth. Under these conditions, BZN inhibits
the parasite growth around 66%; it was also observed that
compounds 4-OH (4), 4-N(CH3)2 (11) and 4-SO2NH2 (16)
showed minor activities.
Fig. 3 Number of epimastigote forms per mL after 72 hours exposure to
20 mg mL1 of compounds 4-H (1), 4-F (5), 4-CH2CH3 (7), 4-Cl (9), 4-CF3
(14), 4-Br (15), 4-I (17), 3,4-Cl2 (19), 3-CF3,4-NO2 (20) and BZN drug.
The values represent the mean of three experiments  SD.
Fig. 4 The activity of the compounds after 72 hours according to the substituent groups selected employing the Craig diagram. (A) At 10 mg mL1; (B)
at 20 mg mL1; (C) at 50 mg mL1. [Adapted with permission from P. N. Craig, Interdependence between physical parameters and selection of substituent
groups for correlation studies, J. Med. Chem., 14, 680–684, Copyright (1971) American Chemical Society].
Fig. 5 Frequency of micronucleated HBEC incubated with benznida-
zole (BZN), compounds 4-H (1), 4-Cl (9), and 4-CF3 (14), at 50 mg mL
1.
The values represent the mean of three experiments  SD (standard
deviation).
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When the compounds were assayed at 50 mg mL1 concen-
tration, compound 4-H (1) demonstrated the best activity after
72 hours of exposure, reducing the concentration of epimastigote
forms to 95% over the culture in the absence of any drug.
Regarding the plots of the PGI values on the Craig diagram
(see Fig. 4), when compounds were tested at 10 mg mL1 better
activity values were found for those containing hydrophobic and
electron-withdrawing groups. However, as soon as the
compounds’ concentration increases, the hydrophobicity
becomes less important to activity, suggesting that there is
a greater availability of hydrophilic compounds in the culture
medium to be absorbed by the parasitic forms, which indicates
the need for a lipo/hydrophilic balance in the design of new
molecules.
The monosubstituted compounds with better activities at
10 mg mL1, 4-Cl (9), 4-CF3 (14) at 50 mg mL
1 4-H (1), and BZN
were selected to investigate genotoxicity.24 The materials and
methods for this procedure are mentioned in the ‘‘Notes and
references’’ section.25 The frequency of micronucleus on Human
Bronchial Epithelial Cells (HBEC) treated for 24 hours was
analyzed (see Fig. 5), and BZN increased the number of micro-
nucleated cells (30.0  3.6) in comparison with the control
(19.0  5.2). This finding is correlated with genotoxic effects.
Otherwise, the compounds 4-H (1), 4-Cl (9), and 4-CF3 (14) did
not significantly induce the increase of the number of micro-
nucleated cells, and their frequency values were 13.0 (3.0), 12.0
(2.1) and 8.0 (4.3), respectively.
These preliminary results pointed out the relevance of the
investigated class of compounds. However, aiming at a better
understanding of the influence of physicochemical properties on
these derivatives’ activity, new protocols to measure the biolo-
gical data (IC50 values) are already being carried out, and will be
reported soon. The IC50 values will be used as dependent vari-
ables in a quantitative structure–activity relationship (QSAR)
approach, which can provide more helpful data for designing
novel potential anti-T. cruzi analogues.
Conclusions
In this study, a set of twenty benzofuroxan derivatives were
biologically assayed against T. cruzi in order to obtain
a preliminary action profile for these compounds. The deriva-
tives presented activity against epimastigote T. cruzi forms,
except for the 4-N(CH3)2 (11) and 4-SO2NH2 (16) compounds
at the three investigated concentrations. The findings indicated
that the anti-T. cruzi activity is influenced by the physico-
chemical properties of the substituent group attached to the
benzene ring. Dissimilar from BZN, the compounds 4-H (1), 4-
Cl (9), and 4-CF3 (14) did not show genotoxic effects. The
results highlighted the importance of these benzofuroxan
derivatives as potential leads for designing novel anti-T. cruzi
drug candidates.
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LSM 700; Leica, Mannheim, Germany). Quantification of
micronuclei was recorded based on observation by counting at least
300 cells.
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